2. Academic Validation
  3. Isosilybin A exhibits anti-inflammatory properties in rosacea by inhibiting MAPK pathway and M1 macrophage polarization

Isosilybin A exhibits anti-inflammatory properties in rosacea by inhibiting MAPK pathway and M1 macrophage polarization

  • Int Immunopharmacol. 2024 Dec 25;143(Pt 1):113323. doi: 10.1016/j.intimp.2024.113323.
Chen-Chen Wu 1,  Jing-Yao Ge 2,  Xin-Yue Huang 2,  Xiao-Ming Liu 1,  Yan Liao 1,  Shui-Jing Zhang 1,  Lin Wu 3,  Xiao-Fan Chen 4,  Bo Yu 5
Affiliations

Affiliations

  • 1 Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong Province, China.
  • 2 Shenzhen Key Laboratory for Translational Medicine of Dermatology, Biomedical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, Guangdong Province, China.
  • 3 Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong Province, China. Electronic address: 119544648@qq.com.
  • 4 Shenzhen Key Laboratory for Translational Medicine of Dermatology, Biomedical Research Institute, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036, Guangdong Province, China. Electronic address: littlecanva@163.com.
  • 5 Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong Province, China; Institute of Dermatology, Shenzhen Peking University - The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, Guangdong Province, China. Electronic address: Drboyu_derm@126.com.
PMID: 39405940 DOI: 10.1016/j.intimp.2024.113323
Abstract

Rosacea is a chronic inflammatory skin disease, which is prone to flares and requires continuous management and treatment. However, long-term use of drugs can lead to additional adverse drug reactions. Based on the comorbid relationship between rosacea and Parkinson's disease, bioinformatics and network pharmacology analysis were used to identify a safer drug for rosacea. It has been demonstrated that ISA has an ameliorative impact on the symptoms of Parkinson's disease. The results demonstrated that ISA exhibited anti-inflammatory properties, including reducing erythema areas and inflammatory cell infiltration in rosacea-like mice models, and inhibiting the expression of inflammatory factors in cellular inflammation models. Furthermore, the anti-inflammatory effect of ISA was associated with inhibition of the ERK, p38 and NF-κB signaling pathways and inhibition of macrophage polarization to M1 type. In addition, molecular docking and drug affinity responsive target stability experiment results indicated that VEGFA and RELA were the direct targets of ISA in the treatment for rosacea. In conclusion, these results suggested that ISA may be a potential therapeutic agent for rosacea.

Keywords

Isosilybin A; Keratinocyte; Macrophage; Rosacea.

Figures
Products
Inhibitors & Agonists
Other Products